Hassman Research Institute

Berlin, New Jersey 08900

0 studies enrolling now · 114 studies all time

What they study most

ADHD, ADHD - Combined Type, Abdominal Pain, Acute Schizophrenia, Adenoviral Conjunctivitis, Adhesive Capsulitis, Adjunctive Treatment of Major Depressive Disorder, Alopecia, Androgenetic, Alzheimer Disease, Alzheimer's Disease, Antipsychotic Agents, Anxiety Generalized

Studies at this site

• A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation — Running, not enrolling
• Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency — Completed
• A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss — Completed
• Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode — Running, not enrolling
• Zelquistinel in the Treatment of Major Depressive Disorder — Completed
• A Study of Psilocybin for Major Depressive Disorder (MDD) — Completed
• Zelquistinel in the Treatment of Adults With Major Depressive Disorder — Completed
• A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms — Completed
• Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder — Stopped early
• Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users — Completed
• GV101 in Healthy Obese Participants — Completed
• Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 — Completed
• Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD — Running, not enrolling
• Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder — Completed
• A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication — Completed
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Running, not enrolling
• An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) — Completed
• Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) — Completed
• A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder — Completed
• Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD) — Completed
• This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months — Stopped early
• A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD — Completed
• SUBLOCADE Rapid Initiation Study — Completed
• SUBLOCADE Rapid Initiation Extension Study — Completed
• Safety and Efficacy of HB-1 for Panic Disorder — Completed
• Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects — Completed
• Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) — Stopped early
• Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I) — Completed
• An Adjunct Study to Assess Guided ADHD Therapy for Managing the Extent and Severity of Symptoms — Running, not enrolling
• Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days — Completed
• A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3) — Completed
• A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication — Completed
• Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) — Completed
• A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder — Completed
• An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4) — Completed
• Effect of PP-01 on Cannabis Withdrawal Syndrome — Completed
• Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity — Stopped early
• A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) — Status unconfirmed
• Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults — Completed
• Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301) — Completed
• A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD — Completed
• Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function — Stopped early
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza — Completed
• Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis — Stopped early
• Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD — Completed
• Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis — Stopped early
• A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia — Completed
• A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication — Completed
• Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain — Completed
• Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD — Completed